HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Luiz Eduardo Wildemberg Selected Research

Acromegaly

11/2023Long-term Efficacy and Safety of Pasireotide in Patients With Acromegaly: 14 Years of Single-Center Real-World Experience.
2/2023miR-383-5p, miR-181a-5p, and miR-181b-5p as Predictors of Response to First-Generation Somatostatin Receptor Ligands in Acromegaly.
11/2022Routine Evaluation of Somatostatin Receptor Type 2 in Patients With Acromegaly: Do We Still Need More Evidence?
1/2022The Future of Somatostatin Receptor Ligands in Acromegaly.
9/2021gsp Mutation Is Not a Molecular Biomarker of Long-Term Response to First-Generation Somatostatin Receptor Ligands in Acromegaly.
1/2021Machine Learning-based Prediction Model for Treatment of Acromegaly With First-generation Somatostatin Receptor Ligands.
1/2019Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles.
3/2018MANAGEMENT OF ENDOCRINE DISEASE: Personalized medicine in the treatment of acromegaly.
1/2018Molecular evidence and clinical importance of β-arrestins expression in patients with acromegaly.
1/2018Treatment escape reduces the effectiveness of cabergoline during long-term treatment of acromegaly in monotherapy or in association with first-generation somatostatin receptor ligands.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Luiz Eduardo Wildemberg Research Topics

Disease

14Acromegaly
11/2023 - 12/2011
10Neoplasms (Cancer)
11/2023 - 12/2011
3Adenoma (Adenomas)
04/2024 - 05/2015
3Cushing Syndrome
12/2023 - 10/2022
2Hyperglycemia
10/2022 - 01/2016
2Headache (Headaches)
01/2022 - 12/2021
2Pituitary Neoplasms (Pituitary Adenoma)
05/2015 - 01/2013
1Mental Disorders (Mental Disorder)
10/2022
1Craniopharyngioma (Craniopharyngiomas)
06/2022
1Carcinoma (Carcinomatosis)
12/2021
1Galactorrhea
12/2021
1Hyperprolactinemia
12/2021
1Hypogonadism (Hypergonadotropic Hypogonadism)
12/2021
1Vision Disorders (Hemeralopia)
12/2021
1Prolactinoma (Prolactinomas)
12/2021
1Intracranial Hypertension
12/2021
1Pituitary Apoplexy
04/2018
1Endocrine System Diseases (Endocrine Diseases)
03/2018
1Residual Neoplasm
05/2015
1Hypertension (High Blood Pressure)
11/2014
1Diabetes Mellitus
11/2014

Drug/Important Bio-Agent (IBA)

9Somatostatin Receptors (Somatostatin Receptor)IBA
02/2023 - 01/2013
8LigandsIBA
02/2023 - 02/2017
5pasireotideIBA
11/2023 - 01/2016
5Insulin-Like Growth Factor I (IGF-1)IBA
11/2023 - 12/2011
4Somatostatin (Somatotropin Release-Inhibiting Factor)IBA
01/2019 - 01/2013
3CabergolineFDA LinkGeneric
10/2022 - 05/2015
3Biomarkers (Surrogate Marker)IBA
09/2021 - 01/2016
3Messenger RNA (mRNA)IBA
09/2021 - 01/2013
2ProlactinIBA
04/2024 - 12/2021
2Growth Hormone (Somatotropin)IBA
11/2023 - 02/2023
2Hormones (Hormone)IBA
01/2022 - 12/2021
2Octreotide (Sandostatin)FDA LinkGeneric
01/2022 - 01/2017
2Proteins (Proteins, Gene)FDA Link
09/2021 - 05/2015
2Dopamine Receptors (Dopamine Receptor)IBA
01/2019 - 05/2015
1GlucocorticoidsIBA
12/2023
1Adrenocorticotropic Hormone (ACTH)FDA Link
11/2023
1MicroRNAs (MicroRNA)IBA
02/2023
1somatostatin receptor 2IBA
11/2022
1CateninsIBA
06/2022
1DNA (Deoxyribonucleic Acid)IBA
06/2022
1RNA (Ribonucleic Acid)IBA
06/2022
1lanreotide (Somatuline)FDA Link
01/2022
1Temozolomide (Temodar)FDA LinkGeneric
12/2021
1GTP-Binding Proteins (G-Protein)IBA
09/2021
1FilaminsIBA
01/2019
1ArrestinsIBA
01/2018
1ABO Blood-Group SystemIBA
11/2014

Therapy/Procedure

6Therapeutics
10/2022 - 01/2013
1Radiotherapy
10/2022
1Procedure Contraindications
10/2022
1Conservative Treatment
04/2018
1Precision Medicine
03/2018